TEVA is the largest maker of generic prescription drugs in the universe, and amongst the largest prescription drug companies globally. Teva boasts a market cap of 33.67 billion, doing it a big cap market leader. TEVA has to boot launched an OOC ( over the counter ) drug venture, doing officially prescription merely drugs accessible without a prescription. Teva non merely produces generics and OOC, but besides has a branded prescription drug unit every bit good. Teva aims to capitalise on an aging population, economic force per unit area placed on the authorities to supply low-cost health care, and the turning importance of OOC medicines.

Teva has significantly strengthened their OTC concern through a joint venture with Procter and Gamble Company approved on November 12, 2012. The companies will ab initio aim 1.3 billion dollars in gross revenues, with mark gross of 4 billion in the following 10 old ages. Additionally TEVA has strengthened both their trade name and market portion with the add-on of Cephalon ‘s branded pharmaceutical concern. The add-on of Cephalon significantly increased TEVA ‘s purchase ; nevertheless their 6.2 billion dollar command on the company was a strategic move which will significantly increase grosss in the coming old ages. TEVA

The bulk of Teva ‘s gross is generated from generic pharmaceuticals, at approximately 56 % . Branded prescription drugs account for approximately 35 % of Teva ‘s entire gross. The staying gross watercourse was generated as portion of the joint venture with Proctor and Gamble.

Teva conducts international operations, with about 48 % of all grosss generated in the United States, 31 % in Europe, and 21 % chiefly in Canada, South America, Israel and Russia.

Industry Overview & A ; Competitive Positioning

Industry Analysis

TEVA resides in the extremely competitory pharmaceutical industry, more specifically, the generic pharmaceutical industry. TEVA is the 2nd largest company within this industry by market cap, with a market cap of 32.8B. Companies within this industry develop and sell a broad scope of prescription and over the counter medicines which are used to handle people with physical, mental, and emotional complaints. Harmonizing to the Beareu of Labor Statistics, this industry supports about 300,000 occupations, which include places runing from a assortment of occupation rubrics, including production, research, and fabrication.

A major cost to all houses which reside in this industry is research and development. This procedure is non merely dearly-won, but besides really clip devouring. Once a new drug is discovered, the mean clip for the drug to look on the market is 7-10 old ages. This poses a important slowdown in the return on research and investing costs for these companies. It is estimated that the entire cost of developing a successfully drug is 1.3 billion dollars. Most drug companies formulate several failed drugs before happening a drug which meets rigorous US and European criterions. A major consideration for pharmaceutical companies is the chance cost of investing, every bit good as the investing capital many old ages before any gross from the drug is realized.

In the US, all possible and new drugs must be approved by the FDA as being both safe and effectual in the intervention or bar of specified upsets. This is a drawn-out and thorough procedure, and is normally accompanied by old ages of research lab research, pre-clinical surveies, and eventually human tests. Many pharmaceutical companies apply for a patent upon development of a successful branded drug, which prevents any generic versions of the drug from come ining the market for about 20 old ages. Patent protection allows the patent proprietor to retrieve costs of research and development, every bit good as the realisation of gross of clip.

There is important political and consumer force per unit area placed on companies in this industry to do effectual and safe drugs for a more low-cost monetary value. Trends in this industry include many old branded drugs happening competition in equal but cheaper generic versions. Generic versions are chemically similar drugs or compounds with similar mechanisms of actions. In recent old ages, there has been a big displacement of consumer assurance and penchant to generic merchandises, non merely due to their inexpensive monetary value, but besides increased effectivity.

Economic Factors:

TEVA has set ambitious growing and gross ends for the old ages to follow. TEVA has put in topographic point a scheme to increase market portion in the US- the universe ‘s largest market, every bit good as extra key markets internationally. TEVA believes they will win in their growing aims due to a turning demand for generic pharmaceuticals and a altering political environment which will let people to flock towards cheaper generic opposite numbers. TEVA believes a important part of future growing will ensue in Asia and European markets, which have a low generic incursion rate.

TEVA has historically high R & A ; D costs, which can be attributed to their committedness to be a market leader in drug finds and betterment. TEVA plans to stay a strong rival in the market by continuously puting in their merchandise portfolio. TEVA has committed to capitalising on “ first-to market ” chances in cardinal markets, which will ease growing and gain our portfolio alpha.

A little but important part of TEVA ‘s gross profile is assimilated by branded proprietary pharmaceuticals. TEVA has strategized to go on to construct their branded pharmaceutical profile through internal R & A ; D, while at the same time broadening geographic enlargement of bing merchandise portfolios. TEVA plans to beef up their bing strengths as a taking development and distributer in drugs handling the cardinal nervous system, respiratory, and adult female ‘s wellness, while spread outing their research into niche curative countries offering limitless gross potency, such as oncology.

Competitive factors

The pharmaceutical industry which TEVA resides is located in a extremely competitory landscape, frequently categorized by transporting competitory forces by part and drug type. Generally, many companies who formulate and produce expensive banded pharmaceuticals will try to register statute law trying to forestall or detain the timely blessing and release of generic less expensive equivalents. Several tactics may be employed, including legislative enterprises, widening patent protection, altering dose recommendations prior to the termination of the patent, or negative Public advertizement runs.

Canada: Foreign rivals in this part continue to do increasing fight in both branded and generic capacities. Additionally, the presence of smaller communality pharmaceutics has become progressively strong competition, as smaller pharmaceuticss are take downing supply concatenation fees and presenting cheaper merchandises.

Europe: TEVA is the taking pharmaceutical distributer and maker in the bulk of European states including UK, Netherlands, Spain, Portugal, Hungry and Italy. TEVA ‘s chief scheme is to go on to spread out operations in Europe, remain a market leader, and capitalise on pro-generic authorities reforms in these cardinal states.

Industry Regulations

The pharmaceutical industry resides in an of all time altering economic landscape. This industry and the companies which constitute it are capable to political force per unit areas, health care reform motions, and progressively rigorous blessing criterions and statute law.

In the United States, president Obama ‘s health care reform will increase TEVA gross in the long tally. The health care reform seeks to do medical specialties and specifically generic medical specialties readily available and more low-cost to all citizens, non merely those who carry medical insurance. Increasing political force per unit area on pharmaceutical companies to supply people with cheaper generics have been a positive promotion for generic companies such as TEVA. Peoples are anticipating generic equivalents, and even prefer generics to their branded options. Due to increased industry ordinances and political force per unit areas, branded rivals are less able to be granted with patent extensions.

Investing Hazards

Ability to introduce

An built-in portion of TEVA ‘s continued success is their ability to introduce and cultivate new merchandises, better bing merchandises, and efficaciously market and sell developed merchandises. TEVA ‘s success is contingent upon their ability to commercialize bing medical specialties, which is both clip consuming, expensive, and involves a drawn-out blessing procedure for distribution.

Industry Regulations

TEVA ‘s profitableness is reliant upon success is disputing patent rights held by 3rd party proprietors of branded equivalents. TEVA relies on the ability to present generic equivalents in a timely mode, as they pride themselves on being a “ first respondent ” when patent duties expire. Any inability to present generic equivalents, successfully develop generics, challenge run outing patents, or base on balls regulative criterions will adversely and materially affect TEVA ‘s gross and overall concern success.

Grosss and enlargement are closely tied with TEVA ‘s ability to obtain exclusivity in the US markets

TEVA ‘s ability to keep continued gross revenues growing and profitableness is extremely dependent on their ability to continually dispute patents, launch new and advanced merchandises, expand positive public dealingss campaigns environing generic equivalents, and administer non-infringing merchandises with increased complexness will establish chances for TEVA in the United States as the health care reform takes topographic point. Any inability to make the above actions can and probably will hold a material negative impact on TEVA ‘s gross and concern success.

Legal actions taken against TEVA will hold inauspicious stuff impact on TEVA ‘s repute and overall profitableness

Quality control jobs, inauspicious and non-listed side effects, negative public dealingss associating to the release of generic medicines may adversely impact TEVA ‘s repute for high quality equivalents and demand dearly-won redress. TEVA must register all production and research installations with the FDA and similar regulative bureaus both domestically and abroad. Therefore, TEVA is capable to regular reviews in conformity with Good fabrication guidelines. Any inefficiency which may potentially be discovered topics TEVA to expensive mulcts, drawn-out probes, and negative imperativeness. Such inefficiency may besides forestall TEVA from let go ofing new merchandises in a timely and efficient mode, therefore contradicting their competitory advantage in the United States and other key markets.

As a taking generic supplier, TEVA ‘s merchandises are invariably scrutinized by both public and private entities, consumers, and rivals. TEVA is invariably under the limelight for drug interactions, non-listed side effects, or other complications associating to the drug which may or may non be due to TEVA ‘s generic drug composing. Public cases, which have the capacity to go on anytime, can non merely be damaging to TEVA ‘s immaculate repute, but can besides be extremely expensive if TEVA is found guilty of any malpractice or error. Any legal strong belief or commendation implicating TEVA in wrongdoing will hold a material inauspicious fiscal and perceptive impact on the company.

TEVA may be unable to successfully get new chances, therefore stunting growing and go forthing TEVA ‘s operations susceptible to competition

TEVA employs an aggressive and ambitious growing scheme, which requires continual acquisitions of both the competition and succinct companies which may spread out TEVA ‘s merchandise line, invention, or market portion. TEVA has historically been able to successfully leverage their size and gross capacity to get smaller companies which will assist TEVA turn, absorb into new merchandise lines, or overpower competition. TEVA ‘s trust on acquisitions as a agency of growing involves hazards that could negatively impact their concern scheme. For illustration, should TEVA fail to properly identify and get companies which will be comfortable and advantageous to their concern scheme, TEVA ‘s competition with trade name companies to get suited campaigners has intensified, hence potentially stunting TEVA ‘s growing should no suited options become available, may materially negatively impact TEVA ‘s ability to turn, introduce, and remain a market leader.